Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Osteosarcoma × fluzoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 2 Breast Neoplasms 2 Sarcoma, Ewing 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplasm Metastasis 1 Her-2 Negative Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Breast Cancer Metastatic 1 Advanced Solid Tumors 1

Interventions

fludarabine 5 Cyclophosphamide 5 Temozolomide 4 cabozantinib 3 Zoledronic Acid 3 Gemcitabine 3 Doxorubicin 3 irinotecan sucrosofate 2 atezolizumab 2 Vincristine 2 Sunitinib 2 Specimen Handling 2 Radiosurgery 2 Methotrexate 2 Irinotecan 2 Ifosfamide 2 Disulfiram 2 Cisplatin 2 Biopsy 2 vactosertib 1 trametinib 1 talazoparib 1 surufatinib 1 silmitasertib 1 selinexor 1 regorafenib 1 penpulimab 1 pegylated granulocyte colony-stimulating factor 1 pegfilgrastim 1 pazopanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06074692 2023-10-31

PRIMA

Ruijin Hospital

Phase 2 Recruiting

Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡